Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinomaR Elaidi, A Harbaoui, B Beuselinck, et al.
The Journal of Urology|August 21, 2002
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier, J P Droz, F Rolland, et al.
British Journal of Cancer|May 17, 2007
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trialP Kerbrat, H Roché, J Bonneterre, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2015
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancerA Gonçalves, J-Y Pierga, J-M Ferrero, et al.
ESMO Open|August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD studyR de Wit, C Wülfing, D Castellano, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2021
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosisT Gaillard, M Carton, A Mailliez, et al.
ESMO Open|June 19, 2024
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS studyP Barthélémy, L Albigès, B Escudier, et al.
British Journal of Cancer|April 3, 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutationJ-S Frenel, A Lusque, S Delaloge, et al.
Breast (Edinburgh, Scotland)|November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC databaseP Gougis, M Carton, C Tchokothe, et al.
Pageof 3